Abstract
Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Volume: 10 Issue: 2
Author(s): Charles J. Malemud
Affiliation:
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Abstract: Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Export Options
About this article
Cite this article as:
J. Malemud Charles, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (2) . https://dx.doi.org/10.2174/1871523011107020073
DOI https://dx.doi.org/10.2174/1871523011107020073 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Microarray Technology as a Universal Tool for High-Throughput Analysis of Biological Systems
Combinatorial Chemistry & High Throughput Screening Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Immunogenicity of Biotherapeutics: A Need for Consensus on Flexibility of Approach (Guest Editor: Stewart Barker)]
Current Drug Safety Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design The Role of Mast Cells in the Structural Alterations of the Airways as a Potential Mechanism in the Pathogenesis of Severe Asthma
Current Pharmaceutical Design Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Optimized Methods for In Vitro and In Vivo Anti-Inflammatory Assays and Its Applications in Herbal and Synthetic Drug Analysis
Mini-Reviews in Medicinal Chemistry From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis
Current Pharmaceutical Design Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets Chemokines and Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry